Investigational Drug Information for AZD2014
✉ Email this page to a colleague
What is the development status for investigational drug AZD2014?
AZD2014 is an investigational drug.
There have been 33 clinical trials for AZD2014.
The most recent clinical trial was a Phase 2 trial, which was initiated on April 15th 2015.
The most common disease conditions in clinical trials are Lung Neoplasms, Breast Neoplasms, and Neoplasms. The leading clinical trial sponsors are AstraZeneca, Samsung Medical Center, and Cancer Research UK.
There are ninety-seven US patents protecting this investigational drug and one international patent.
Summary for AZD2014
| US Patents | 97 |
| International Patents | 1,232 |
| US Patent Applications | 446 |
| WIPO Patent Applications | 308 |
| Japanese Patent Applications | 81 |
| Clinical Trial Progress | Phase 2 (2015-04-15) |
| Vendors | 69 |
Recent Clinical Trials for AZD2014
| Title | Sponsor | Phase |
|---|---|---|
| Phase II Trial of Vistusertib（AZD2014） Single Agent in TSC1or 2 Null or TSC 1/2 Mutation Solid Cancer Patients Refractory to Standard Chemotherapy | Samsung Medical Center | Phase 2 |
| Phase II Trial of AZD2014 in RICTOR Amplified Solid Cancer Patients Refractory to Standard Chemotherapy | Samsung Medical Center | Phase 2 |
| Navitoclax and Vistusertib in Treating Patients With Relapsed Small Cell Lung Cancer and Other Solid Tumors | National Cancer Institute (NCI) | Phase 1/Phase 2 |
Clinical Trial Summary for AZD2014
Top disease conditions for AZD2014
Top clinical trial sponsors for AZD2014
US Patents for AZD2014
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| AZD2014 | ⤷ Try a Trial | Low, immune enhancing, dose mtor inhibitors and uses thereof | Novartis AG (Basel, CH) | ⤷ Try a Trial |
| AZD2014 | ⤷ Try a Trial | Pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mTOR inhibitors | KuDOS Pharmaceuticals Limited (London, GB) | ⤷ Try a Trial |
| AZD2014 | ⤷ Try a Trial | 7-benzyl-4-(methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]- pyrimidin-5 (1h)-one, salts thereof and methods of using the same in combination therapy | Oncoceutics, Inc. (Philadelphia, PA) | ⤷ Try a Trial |
| AZD2014 | ⤷ Try a Trial | Heterocyclic estrogen receptor modulators and uses thereof | Genentech, Inc. (South San Francisco, CA) | ⤷ Try a Trial |
| AZD2014 | ⤷ Try a Trial | Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases | ZHEJIANG DTRM BIOPHARMA CO. LTD. (Hangzhou, CN) | ⤷ Try a Trial |
| AZD2014 | ⤷ Try a Trial | mTORC1 inhibitors | The Regents of the University of California (Oakland, CA) | ⤷ Try a Trial |
| AZD2014 | ⤷ Try a Trial | Chemical compounds | AstraZeneca AB (Sodertalje, SE) | ⤷ Try a Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for AZD2014
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| AZD2014 | Australia | AU2014348657 | 2033-11-13 | ⤷ Try a Trial |
| AZD2014 | Australia | AU2017245411 | 2033-11-13 | ⤷ Try a Trial |
| AZD2014 | Australia | AU2019246853 | 2033-11-13 | ⤷ Try a Trial |
| AZD2014 | Brazil | BR112016010716 | 2033-11-13 | ⤷ Try a Trial |
| AZD2014 | Canada | CA2929181 | 2033-11-13 | ⤷ Try a Trial |
| AZD2014 | China | CN105899232 | 2033-11-13 | ⤷ Try a Trial |
| AZD2014 | Eurasian Patent Organization | EA201690987 | 2033-11-13 | ⤷ Try a Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
